Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Trials

The aims of the GHSG’s current trials are to further optimize first-line treatment in all stages of Hodgkin lymphoma and to improve therapy for relapsed patients, while minimizing treatment-related adverse effects and maintaining treatment efficacy.

Active trials

First-line treatment

Brief denomination Title Stage Design
HD17 Treatment optimization trial in the first-line treatment of intermediate stage Hodgkin lymphoma; treatment stratification by means of FDG Intermediate stage Phase III, multicenter, randomized
HD16 Treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET Early stages Phase III, multicenter, randomized
HD18 Treatment optimization trial in the first-line treatment of Hodgkin lymphoma; treatment stratification by means of FDG-PET Advanced stages Phase III, multicenter, randomized

Treatment of relapses

Brief denomination Title Stage Design
HD-R3i     Phase I/II, multicenter, randomized(only Phase II)

Trials in Preparation

Brief denomination Title Stage Design